<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Qato DM</submitter><funding>NCATS NIH HHS</funding><funding>UMB ICTR</funding><pagination>350</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8091773</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>21(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Little is known about benzodiazepine and opioid-benzodiazepine co-dispensing patterns among pregnant women. Understanding these patterns is necessary to mitigate high-risk medication use during pregnancy. Our objective in this analysis was to evaluate opioid and benzodiazepine dispensing and co-dispensing patterns among commercially insured pregnant women in the United States.&lt;h4>Methods&lt;/h4>This retrospective study used a 10% random sample of commercially insured enrollees from the IQVIA™ Adjudicated Health Plan Claims Data from 2007 to 2015. The study included women (12-55 years of age) with completed pregnancies who had continuous medical and prescription drug coverage from 3 months prior to the date of conception through 3 months post-delivery. We estimated the preva</pubmed_abstract><journal>BMC pregnancy and childbirth</journal><pubmed_title>Opioid and benzodiazepine dispensing and co-dispensing patterns among commercially insured pregnant women in the United States, 2007-2015.</pubmed_title><pmcid>PMC8091773</pmcid><funding_grant_id>1UL1TR003098-01</funding_grant_id><funding_grant_id>UL1 TR003098</funding_grant_id><pubmed_authors>Gandhi AB</pubmed_authors><pubmed_authors>Qato DM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Opioid and benzodiazepine dispensing and co-dispensing patterns among commercially insured pregnant women in the United States, 2007-2015.</name><description>&lt;h4>Background&lt;/h4>Little is known about benzodiazepine and opioid-benzodiazepine co-dispensing patterns among pregnant women. Understanding these patterns is necessary to mitigate high-risk medication use during pregnancy. Our objective in this analysis was to evaluate opioid and benzodiazepine dispensing and co-dispensing patterns among commercially insured pregnant women in the United States.&lt;h4>Methods&lt;/h4>This retrospective study used a 10% random sample of commercially insured enrollees from the IQVIA™ Adjudicated Health Plan Claims Data from 2007 to 2015. The study included women (12-55 years of age) with completed pregnancies who had continuous medical and prescription drug coverage from 3 months prior to the date of conception through 3 months post-delivery. We estimated the preva</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 May</publication><modification>2026-07-16T10:30:28.047Z</modification><creation>2025-04-07T00:06:26.268Z</creation></dates><accession>S-EPMC8091773</accession><cross_references><pubmed>33941106</pubmed><doi>10.1186/s12884-021-03787-5</doi></cross_references></HashMap>